Treatment sequencing and emerging strategies in multiple myeloma—connecting the right nodes in the right order
memo - Magazine of European Medical Oncology · 07.08.2026
DOI: 10.1007/s12254-026-01121-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift memo - Magazine of European Medical Oncology, online erschienen am 07.08.2026. Verfasst von Klaus Podar. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Technopol.
Abstract (Originalsprache)
The treatment of multiple myeloma (MM) has been (r)evolutionized by the approval of 20 new agents and more than 30 new regimens over the past two decades, with population-based data indicating that the 5‑year relative survival rate now approaches 64% and emerging evidence of functional cure in at least a subset of patients. Chimeric antigen receptor (CAR) T‑cell therapies and bispecific antibodies (bsAbs) represent the latest (r)evolutionary step, increasingly moving from later into earlier treatment lines and further expanding the complexity of treatment sequencing in MM. With the armamentarium continuing to expand rapidly, identifying the optimal treatment sequence from the multitude of currently available options has become a critical determinant of therapeutic success. This short review discusses current evidence and practical guidance on treatment sequencing in MM, with a particular focus on CAR T‑cell therapies and bsAbs.
Förderung
- Technopol
Zitieren
APA
Podar, K. (2026). Treatment sequencing and emerging strategies in multiple myeloma—connecting the right nodes in the right order. memo - Magazine of European Medical Oncology. https://doi.org/10.1007/s12254-026-01121-3
Vancouver
Podar K. Treatment sequencing and emerging strategies in multiple myeloma—connecting the right nodes in the right order. memo - Magazine of European Medical Oncology. 2026. doi:10.1007/s12254-026-01121-3
BibTeX
@article{Podar2026,
author = {Podar, Klaus},
title = {Treatment sequencing and emerging strategies in multiple myeloma—connecting the right nodes in the right order},
journal = {memo - Magazine of European Medical Oncology},
year = {2026},
doi = {10.1007/s12254-026-01121-3}
}
EUVIMED